Since SCD-1 acts as a key mediator in the hepatic DNL process, SCD-1 might be the potential therapeutic target of the GC combination in improving hepatic lipid accumulation in NAFL rodent models. This evidence concerns the gene SCD and non-alcoholic fatty liver.